Enanta Starts Phase 2b Study of EDP-938 in Respiratory Syncytial Virus

  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the elderly and/or those with congestive heart failure, chronic obstructive pulmonary disease (COPD) or asthma.

https://www.biospace.com/article/releases/enanta-pharmaceuticals-initiates-a-phase-2b-clinical-study-of-edp-938-in-high-risk-adults-with-respiratory-syncytial-virus/